Leaders from eight associations representing the UK and EU pharmaceutical market have written a joint letter to chief Brexit negotiators Michel Barnier and David Davis, reaffirming the importance that the Brexit deal will have on the industry. Getting an early deal on medicines regulation “is the best way of ensuring that patients across Europe and the UK are able to continue to access safe and effective medicines and to ensure that there is no adverse impact on public health”, say the industry bodies.
The pharmaceutical and medical device market are heavily integrated into the EU framework which means there is little certainty around the current industry’s future. Last week, UK health secretary Jeremy Hunt and business secretary Greg Clark said in a letter to the Financial Times that the UK “would like to find a way to continue to collaborate with the EU” on the regulation of medicines after 30 March 2019 – the date when the UK officially leaves the EU under the two-year Article 50 process. The industry associations’ letter welcomes that move and says “we would like to explore this possibility to maintain close regulatory ties between the EU and the UK and to begin these discussions immediately”.